Gain Therapeutics, Inc. reports promising results from its Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson’s disease. The study indicates the therapy is safe and well-tolerated, enhancing GCase enzyme function, which is pivotal in combating the disease’s progression.
Meet Gain Therapeutics’ New Chief Medical Officer: Dr Jonas Hannestad, MD, PhD
This blog discusses Parkinson’s Disease, highlighting its history, characteristics, and ongoing research. Initiatives like the PD GENEration study offer free genetic testing. Gain Therapeutics is developing GT-02287, a potential disease-modifying drug for GBA1-Parkinson’s, with support from prominent foundations and currently conducting clinical trials.
On Wednesday, March 29th, Hartaj Singh (Oppenheimer Senior Research Biotechnology Analyst) moderated a virtual Fireside Chat panel with Gain Therapeutics’ CTO Xavier Barril, Ph.D. and
Virtual Fireside Chat: Computational Biology in Drug Discovery with Gain Therapeutics (GANX) CTO & Two Experts on Wednesday, March 29th at 12:00 p.m. EDT Listen
Download: SEE-Tx® Platform
Download: Lead Program in GBA-Parkinson’s Disease
You joined Gain Therapeutics in 2020 when it was a private company and played a role in helping to take the company public. What was
Listen to Podcast Watch the full presentation video of Computational Drug Discovery With Gain Therapeutics Matthias Alder In conversation with Mathias Alder, CEO of Gain
What scientific innovation are you most excited about? Which innovation do you think will have the most impact in the next 20 years? I don’t
Your educational background is in law. What was the trajectory of your career? Well, it was an evolution. Throughout my career, I’ve always been involved
Watch the full presentation video of Jeff Harman with Eric Richman, CEO of Gain Therapeutics: 00:01 I am Jeff Harmon 00:14 Eric Richman 00:19 Gain
Watch the full presentation video below : 0:00 Jefferies HealthCare Conference 0:24 Forward Looking Statement 0:40 Investment Highlights 02:49 Gain Therapeutics Two-Pronged Approach to Value
Piper Sandler recently published a comprehensive report entitled “Deciphering the Artificial Intelligence / Machine Learning Matrix Code in Biotech.” Why is this report significant? Technology
The Emerging Life Sciences Summit hosted by Oppenheimer will be on July 20th, 2022 in Montauk, NY. This yearly conference brings together the who’s who
“While we continue to see exciting advances across the biopharma innovation landscape, sadly, new approaches and therapies for neurodegenerative diseases continue to remain largely elusive
Dr. Manolo Bellotto, General Manager and President of Gain Therapeutics, shares his personal story. You can follow him on : Twitter : @ManoloBellotto LinkedIn : https://www.linkedin.com/in/manolobellotto/
We sat down and got a chance to speak with the General Manager and President of Gain Therapeutics, Dr. Manolo Bellotto. You can follow him
Gain Therapeutics will be providing an update on our lead compound in development for GBA-associated Parkinson’s disease, GT-02287 at the Jefferies Global Healthcare Conference. Recent
1. What initially sparked your interest in neuroscience? Science has always interested me. Even as a young child I wanted to be a scientist or
What is PROTAC? PROTAC, which is an acronym for proteolysis targeting chimera, is a class of heterobifunctional molecules that can be used to target specific proteins for degradation
How do allosteric drugs compare to more traditional orthosteric drugs? Orthosteric drugs are compounds that bind to the active site of an enzyme. In order
What are prion diseases? Prion diseases are a group of neurodegenerative disorders that affect humans and other mammals. The most recognizable prion diseases are bovine
The presentation by Professor Zoe Cournia, who is at the Biomedical Research Foundation Academy of Athens in Greece, was about the power of supercomputing and
Professor Ricardo Feldman, who is from the University of Maryland School of Medicine, gave a presentation about Gain Therapeutics STAR molecules for the treatment of
Professor Tiago Outeiro who is Professor of Aggregopathies and Director of the Department of Experimental Neurodegeneration at the University Medical Center in Gottingen, Germany, and
Presenting at Gain Therapeutics R&D Day, Manolo Bellotto, Ph. D elaborated on the Broad Application of Gain Therapeutics’ Structurally Targeted Allosteric Regulators (STARs). See the
Speaking at the Gain Therapeutics R&D Day, Dr. Xavier Barril, shared about discovering Novel Allosteric Targets by Combining Advances in Big Data and Computational Technology.
Manolo Bellotto, Ph. D gave an overview of Gain Therapeutics GBA program during Gain Therapeutics R&D Day. He explained how GBA program targets beta-glucocerebrosidase, or
During Gain Therapeutics R&D Day, Samuel Broder, MD shares his perspective on Neuroscience and Beyond. The title of his presentation was “The Role of Allosteric
©2022 Gain Therapeutics, Inc